Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Shores Up Rare Disease Portfolio With Amicus Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal valued at up to $440 million would give the U.K. firm three pharmacological chaperone compounds that could compete with Genzyme products in Gaucher, Fabry and Pompe diseases.

You may also be interested in...



Shire Planning On Significant Growth In Human Genetic Therapies Unit

Firm anticipates increased global reach, eight potential new launches in rare disease therapies by 2015.

Shire Planning On Significant Growth In Human Genetic Therapies Unit

Firm anticipates increased global reach, eight potential new launches in rare disease therapies by 2015.

Amicus Reports Positive Preliminary Data On Plicera For Gaucher Disease

Amicus and partner Shire hope to grab a share of the $1 billion market now dominated by Genzyme’s Cerezyme.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel